Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ATryn Clear all
Terminated Phase 1 Interventional

Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)

NCT01698567
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Antithrombin III, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
1 Day to 180 Days
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 25, 2026, 2:41 AM EDT
Terminated Phase 4 Interventional Results available

Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery

NCT01547728
View directory record Official record
Conditions
Thrombophilia Due to Acquired Antithrombin III Deficiency
Interventions
Recombinant antithrombin (rhAT)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Oct 25, 2026, 2:41 AM EDT
Recruiting Phase 4 Interventional

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

NCT06145373
View directory record Official record
Conditions
Hemophilia A
Interventions
Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC), Emicizumab
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Los Angeles, California • Flowood, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 25, 2026, 2:41 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

NCT05662319
View directory record Official record
Conditions
Hemophilia
Interventions
Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
8
States / cities
Orange, California • Minneapolis, Minnesota • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 25, 2026, 2:41 AM EDT
Recruiting Phase 2Phase 3 Interventional

Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies

NCT04924322
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Enoxaparin
Drug
Lead sponsor
Yale University
Other
Eligibility
Up to 17 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 25, 2026, 2:41 AM EDT
Recruiting No phase listed Observational

Circadian Variation of Anti-Factor Xa in Hospitalized Trauma Patients

NCT07856641
View directory record Official record
Conditions
Circadian Variation in Anti-Factor Xa (Anti-FXa) Activity
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 25, 2026, 2:41 AM EDT
Enrolling by invitation Phase 2 Interventional

Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism

NCT05794165
View directory record Official record
Conditions
Trauma Injury, Thromboembolism, Venous Thromboembolism
Interventions
Thrombate infusion, Placebo
Drug
Lead sponsor
Bryan Cotton
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • Miami, Florida • Jackson, Mississippi + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 25, 2026, 2:41 AM EDT
Terminated Phase 2 Interventional Results available

Antithrombin III in Infectious Disease Caused by COVID-19

NCT04899232
View directory record Official record
Conditions
Antithrombin III Deficiency, Covid19
Interventions
Antithrombin III
Drug
Lead sponsor
Enrique Ginzburg
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support

NCT02631174
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation Complication, Cardiopulmonary Bypass
Interventions
Antithrombin III
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 1 Year
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia

NCT02059135
View directory record Official record
Conditions
Preeclampsia
Interventions
Recombinant human antithrombin (ATryn), Normal Saline 0.9%
Biological · Other
Lead sponsor
rEVO Biologics
Industry
Eligibility
16 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 25, 2026, 2:41 AM EDT
Withdrawn Phase 1 Interventional

Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis

NCT04055389
View directory record Official record
Conditions
Portal Vein Thrombosis, Cirrhosis, Liver
Interventions
Antithrombin III, Placebo
Drug · Other
Lead sponsor
Jonathan Stine
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 25, 2026, 2:41 AM EDT
Completed No phase listed Observational

Long Term Effects of Erythrocyte Lysis

NCT00842621
View directory record Official record
Conditions
Sickle Cell Disease, Hemolytic Anemia
Interventions
Clinical Evaluations, Laboratory Studies
Procedure · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 25, 2026, 2:41 AM EDT
Recruiting Phase 3 Interventional

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

NCT04918173
View directory record Official record
Conditions
Congenital Antithrombin Deficiency
Interventions
Atenativ
Drug
Lead sponsor
Octapharma
Industry
Eligibility
12 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Miami, Florida • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 2:41 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

NCT06096116
View directory record Official record
Conditions
Acquired Antithrombin Deficiency
Interventions
Human plasma derived antithrombin, Placebo
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Stanford, California • Miami, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Results available

Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.

NCT00056550
View directory record Official record
Conditions
Antithrombin Deficiency, Congenital
Interventions
Recombinant Human Antithrombin (rhAT)
Biological
Lead sponsor
rEVO Biologics
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Marietta, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Results available

Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery

NCT00110513
View directory record Official record
Conditions
Antithrombin III Deficiency
Interventions
Recombinant human antithrombin (rhAT)
Biological
Lead sponsor
rEVO Biologics
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2012 · Synced Oct 25, 2026, 2:41 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

NCT07285460
View directory record Official record
Conditions
Hemophilia
Interventions
Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
1 Year to 11 Years · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • Torrance, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 2:41 AM EDT
Withdrawn Phase 4 Interventional

Pharmacokinetic Study of Recombinant AT III in Neonates Undergoing ECMO

NCT01913444
View directory record Official record
Conditions
Neonates on ECMO
Interventions
Recombinant Antithrombin
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Minute to 30 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Oct 25, 2026, 2:41 AM EDT
Completed No phase listed Observational

Hemostatic Profiles in Pediatric CKD

NCT05064267
View directory record Official record
Conditions
Kidney Disease, Chronic, Pediatric Kidney Disease, Renal Insufficiency, Chronic, Blood Coagulation Disorders in Children
Interventions
phlebotomy
Diagnostic Test
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
6 Months to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 25, 2026, 2:41 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis

NCT04380220
View directory record Official record
Conditions
Multiple Sclerosis, Relapse
Interventions
Blood samples and processing
Diagnostic Test
Lead sponsor
Regina Elena Cancer Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Understanding "Heparin Resistance" in Cardiac Surgery

NCT01598883
View directory record Official record
Conditions
Cardiopulmonary Bypass, Altered Heparin Response
Interventions
Heparin, ATryn
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery

NCT02103114
View directory record Official record
Conditions
ATIII Deficiency
Interventions
Anti-thrombin III, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
Up to 7 Months
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 25, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

NCT02037555
View directory record Official record
Conditions
Cardiac Surgery, Cardiopulmonary Bypass
Interventions
AT-III (Human), Placebo
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
41
States / cities
Orange, California • San Francisco, California • Stanford, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 25, 2026, 2:41 AM EDT
Terminated Phase 1 Interventional

Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates

NCT01158729
View directory record Official record
Conditions
Postoperative Hemorrhage
Interventions
Antithrombin (Recombinant), Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Days to 30 Days
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 20, 2014 · Synced Oct 25, 2026, 2:41 AM EDT